Sugi Predict

Sugi Predict / Compounds / SCHEMBL17595012

SCHEMBL17595012

SCHEMBL17595012

Cc1ccc(N)cc1-c1cc(Cl)nc(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLA2G7 Q13093 1/20 0.51
▸ CYP3A4 P08684 2/20 0.48
▸ ALDH1A1 P00352 4/20 0.43
▸ CASP1 P29466 3/20 0.42
▸ TSHR P16473 2/20 0.39
▸ PDE10A Q9Y233 1/20 0.39
▸ RAF1 P04049 1/20 0.39
▸ KDM4E B2RXH2 5/20 0.39
▸ MAPT P10636 5/20 0.39
▸ HSD17B10 Q99714 3/20 0.39
▸ RAB9A P51151 3/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ GAA P10253 2/20 0.39
▸ HPGD P15428 2/20 0.39
▸ RECQL P46063 1/20 0.39
▸ CASP3 P42574 1/20 0.39
▸ SENP8 Q96LD8 1/20 0.39
▸ SENP7 Q9BQF6 1/20 0.39
▸ SENP6 Q9GZR1 1/20 0.39
▸ ABL1 P00519 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31312426 1.00 PLA2G7 (0.51) PLA2G7CYP3A4ALDH1A1CASP1TSHR
SCHEMBL31636298 0.91 PLA2G7 (0.47) PLA2G7CYP3A4ALDH1A1CASP1TSHR
SCHEMBL25699188 0.91 PLA2G7 (0.47) PLA2G7CYP3A4ALDH1A1CASP1TSHR
SCHEMBL25261605 0.89 PLA2G7 (0.45) PLA2G7CYP3A4ALDH1A1CASP1TSHR
SCHEMBL30405473 0.89 PLA2G7 (0.45) PLA2G7CYP3A4ALDH1A1CASP1TSHR
SCHEMBL25594040 0.83 PLA2G7 (0.41) PLA2G7CYP3A4ALDH1A1CASP1TSHR
SCHEMBL31312617 0.81 PLA2G7 (0.47) PLA2G7CYP3A4ALDH1A1CASP1TSHR
SCHEMBL25232645 0.81 PLA2G7 (0.47) PLA2G7CYP3A4ALDH1A1CASP1TSHR
SCHEMBL25983858 0.80 ALDH1A1 (0.38) PLA2G7CYP3A4ALDH1A1CASP1RAF1
SCHEMBL17595037 0.79 POLB (0.45) PLA2G7CYP3A4ALDH1A1CASP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250250235-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2025-08-07 — — US disclosed
US-12319655-B2 RAF kinase inhibitors and methods of use thereof DECIPHERA PHARMACEUTICALS, LLC (US) 2025-06-03 — — US disclosed
EP-4444429-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF Deciphera Pharmaceuticals, LLC (US) 2024-10-16 — — EP disclosed
US-20230357179-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-11-09 — — US disclosed
US-20230357179-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-11-09 — — US disclosed
US-20230257352-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-08-17 — — US disclosed
US-20230257352-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-08-17 — — US disclosed
US-20230257352-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-08-17 — — US disclosed
WO-2023108108-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2023-06-15 — — WO disclosed
WO-2023108108-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2023-06-15 — — WO disclosed
WO-2023108103-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2023-06-15 — — WO disclosed
CN-107074828-B Compounds and compositions as RAF kinase inhibitors 诺华股份有限公司 2020-05-19 — — CN disclosed
EP-3191478-B1 COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS NOVARTIS AG (CH) 2019-05-08 — — EP disclosed
US-10167279-B2 Compounds and compositions as RAF kinase inhibitors NOVARTIS AG (CH) 2019-01-01 — — US disclosed
US-10167279-B2 Compounds and compositions as RAF kinase inhibitors NOVARTIS AG (CH) 2019-01-01 — — US disclosed
US-20180170917-A1 COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2018-06-21 — — US disclosed
US-20180170917-A1 COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2018-06-21 — — US disclosed
US-20180170917-A1 COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2018-06-21 — — US disclosed
EP-3191478-A1 COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS Novartis AG (CH) 2017-07-19 — — EP disclosed
WO-2016038582-A1 COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS NOVARTIS AG (CH) 2016-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12319655-B2 RAF kinase inhibitors and methods of use thereof BRAF, RAF1, ARAF PLA2G7 2531/4885CYP3A4 4349/4885ALDH1A1 2049/4885
US-20230357179-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF PLA2G7 2531/4885CYP3A4 4349/4885ALDH1A1 2049/4885
US-20230257352-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF PLA2G7 2531/4885CYP3A4 4349/4885ALDH1A1 2049/4885
US-20180170917-A1 COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF PLA2G7 1167/4885CYP3A4 4236/4885ALDH1A1 2115/4885
US-20250250235-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF PLA2G7 2531/4885CYP3A4 4349/4885ALDH1A1 2049/4885
US-10167279-B2 Compounds and compositions as RAF kinase inhibitors BRAF, RAF1, ARAF PLA2G7 1167/4885CYP3A4 4236/4885ALDH1A1 2115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.